Floatz logo

PIMURUTAMAB

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

Shanghai Henlius Biotechmonoclonal_antibodyPhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

54 Active assets in the Advanced or Metastatic Squamous Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BBB
Pembrolizumab
Shanghai Henlius Biotech
Phase 3BB
Serplulimab
Shanghai Henlius Biotech
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3BB
Docetaxel
Shanghai Henlius Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

PIMURUTAMAB is also rated in:

squamous cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →